$3.05
+2.7%Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Wall Street analysts project that GNLX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 17.33, with estimates ranging from a low of 16.00 to a high of 20.00.
The consensus 1-year price target stands at 17.33, with estimates ranging from a low of 16.00 to a high of 20.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Moderate growth expected, typical for mature businesses with stable market positions.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Moderate growth expected, typical for mature businesses with stable market positions.
Limited coverage may indicate reduced institutional interest or information availability.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
During the last 12 months, insiders have purchased $3.29M and sold $7.21M worth of GNLX shares, resulting in $3.91M of net selling activity.
0
0.00
20.3K
56.91K
-57K
-$57K
0
0.00
10.0K
28.96K
-29K
-$29K
0
0.00
16.0K
82.06K
-82K
-$82K
904.9K
3.29M
498.3K
7.04M
-3.7M
-$3.75M
Zindrick Thomas
Officer: President And Ceo
$1.74M
Cappello Joseph
Officer: Chief Technical Officer
$519K
Yu Yong
Officer: Svp, Clinical Development
$490K
Smalling Ralph
Officer: Head Of Regulatory
$127K
Tyree James L
Director
$104K
Zindrick Thomas
Officer: President And Ceo
$5.68M
Yu Yong
Officer: Chief Scientific Officer
$1.27M
Thomas John
Director
$109K
Cappello Joseph
Officer: Chief Technical Officer
$88K
Smalling Ralph
Officer: Head Of Regulatory
$61K
Negative insider sentiment with $3.91M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
Continue your GNLX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.